Concomitant chemoradiotherapy with high dose rate brachytherapy as a definitive treatment modality for locally advanced cervical cancer  by Refaat, Tamer et al.
Alexandria Journal of Medicine (2011) 47, 15–24Alexandria University Faculty of Medicine
Alexandria Journal of Medicine
www.sciencedirect.comORIGINAL ARTICLEConcomitant chemoradiotherapy with high dose
rate brachytherapy as a deﬁnitive treatment modality
for locally advanced cervical cancerTamer Refaat a,*, Amr Elsaid a, Nashaat Lotfy a, Krystyna Kiel b,
William Small Jr. c, Phillip Nickers d, Eric Lartigau da Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Alexandria University, Egypt
b Rush Cancer Center, Rush University, Chicago, IL, USA
c Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
d Oscar Lambret Comprehensive Cancer Center, Lille II University, FranceReceived 5 October 2010; accepted 12 December 2010
Available online 12 June 2011*
E
ed
20
Pr
Pe
M
doKEYWORDS
Cervical cancer;
HDR;
Brachytherapy;
ChemoradiationCorresponding author. Tel.
-mail addresses: Tamermr
u.eg (T. Refaat).
90-5068 ª 2011 Alexandr
oduction and hosting by Els
er review under responsibilit
edicine.
i:10.1016/j.ajme.2010.12.002
Production and h: +20 01
@yahoo.
ia Univ
evier B.V
y of Ale
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local control and survival of patients with cervix cancer treated by external beam radiotherapy
(EBR) and high-dose-rate (HDR) brachytherapy concomitant with weekly Cisplatin chemotherapy.
Methods: Forty patients with FIGO Stages IB2 and II were treated. The mean age was 48.49 years.
EBR to the whole pelvis TO 45 Gy in 25 fractions was given to all patients. Aparametrial boost was
given in 60% of patients, to a median dose of 9 Gy. Brachytherapy with HDR was performed dur-
ing or after completing EBR with a dose of 24 Gy in four fractions of 6 Gy delivered weekly to
point ‘‘A’’ or in some patients who were planned on MRI image guided brachytherapy with dose
prescribed to high risk clinical target volume (CTV). Patient age, tumor stage, and presence or
absence of comorbid conditions as diabetes mellitus, ischemic vascular disease and collagen disease21037104.
com, tamer.refaat@alexmed.
ersity Faculty of Medicine.
. All rights reserved.
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16 T. Refaat et al.and total dose to right and left point ‘‘A’’ were variables analyzed for treatment induced toxicities,
survival and local control.
Cumulative biologic effective dose (BED) at rectal and bladder reference points were correlated
with treatment complications in these organs.
Results: The most common acute toxicities included grade 1 and 2 fatigue (30%), diarrhea (25%),
decreased neutrophil count (25%) and anemia (22.5%). Only 5% of the patients developed grade 3
rectal complications (proctitis and rectal bleeding) and 10% developed grade 1 or 2 rectal compli-
cations. Regarding urinary complications, 12.5% developed grade 1 or 2 toxicities.
Mean follow-up time was 20 months. Overall survival, disease-free survival, and local control were
100%, 92.5 %, and 95%, respectively. One patient developed bone metastases and two patients
developed local relapse.
Conclusion: This study suggests that concomitant chemoradiotherapy with 45 Gy to the whole
pelvis concomitant with cisplatin chemotherapy and four fractions of 6 Gy to point ‘‘A’’ with
HDR brachytherapy is an effective and tolerable fractionation schedule in the treatment of Stages
IB2 and II cervix cancer.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
It is estimated that 12,200 women will be diagnosed with and
4210 women will die of cancer of the cervix uteri in 2010 X
CLOSE Table I-1 (http://seer.cancer.gov/scr/1975_2007/
results_single/sect/sect_01_table.01.pdf). Incidence and mortal-
ity associated with cervical cancer are higher among minorities,
as illustrated by the American Cancer Society Statistics. The
incidence of cervical cancer for Hispanics (14.2/100,000) is al-
most double that for non-Hispanic whites (7.3/100,000), and
3% of cancer deaths in Hispanics are due to cervical cancer.
The incidence of cervical cancer is about 30% higher in African
Americans (11.5/100,000) than in whites, with about twice the
mortality (5.0 versus 2.4/100,000), representing 2% of cancer
deaths in African American women.1
Global incidence and mortality rates are even more dispa-
rate. However, there has been a 75% decrease in the incidence
and mortality of cervical cancer over the past 50 years in devel-
oped countries. The cervical cancer is the second most com-
mon cause of cancer-related morbidity and mortality among
women in developing countries. In 2002, in developing coun-
tries, 493,243 new cases were observed and 273,606 deaths,
with a 55% mortality rate. Eighty-three percent of all cases
of cervical cancer worldwide occur in developing countries,
resulting in a cumulative risk of 1.5 percent for developing cer-
vical cancer by age 65 years.2 Approximately 70% of cervical
cancers are squamous cell carcinomas (SCCs), 25% adenocar-
cinomas, and 3–5% adenosquamous carcinomas.3
The risk of metastasis to lymph nodes in patients with
stages IB2 and II cervical cancer is much higher than that in
patients with stage IB1 disease (30–50% versus 15–25%) and
the subsequent 5 year survival rate is lower (60–70% versus
80–90%).4,5
Until recently, women with cancer with these stages under-
went radical hysterectomy or received radiation therapy alone.
To improve these incomes, chemotherapy has been added to
radiation therapy. Concurrent chemotherapy with radiation
treatment is now standard treatment in these stages of disease.
The synergistic effect of chemotherapy and radiation therapy
reduces the tumor hypoxic fraction, synchronizes cell cycles,
inhibits cellular repair, and recruits non-proliferating cells into
cell cycles. These effects account for the improved treatmentefﬁcacy obtained with concurrent chemo-radiation as opposed
to irradiation alone.6–10
In 1999, the US National Cancer Institute announced its
support of concurrent cisplatin-based chemotherapy and radi-
ation therapy in women with cervical treated with radiation
therapy. This was based on data from ﬁve randomized con-
trolled trials that showed a signiﬁcant beneﬁt of concurrent
chemo-radiation either as postoperative adjuvant therapy in
patients with high risk factors or primary therapy in patients
with locally advanced cervical cancer. All ﬁve trials utilized
concurrent cisplatin either alone or in combination with 5-ﬂu-
orouracil (5-FU) or 5-FU and hydroxyurea.6–10
Generally, radiation therapy for cervical cancer consists of
a combination of external whole pelvic irradiation (ERT) and
intracavitary irradiation (ICRT). The aim is to eradicate can-
cer in the primary site, paracervical tissue, and regional pelvic
LNs.11 ERT is given initially to decrease the bulk of the tumor,
which in turns allows better geometric anatomy to allow opti-
mal dose delivery in ICRT. ERT also covers parametrium, pel-
vic side wall and regional lymph nodes. ICRT is often
delivered with uterine tandem and vaginal ovoids to provide
a high radiation dose to the cervix tumor after it is partially
shrunken by ERT. This application of ICRT has been proven
by many authors to reduce the rate of local failure and to im-
prove the survival rate compared with ERT alone: 78% versus
53% for local control12 and 43–87% versus 21.0–60.5% for
survival.12–14
Low-dose-rate brachytherapy has long been used,15 but
immobilization and hospitalization of patients and exposure
of medical personnel to radiation have been by-products.
There has been increasing use of the high-dose-rate technique
in the recent years which reduces hospitalization, takes advan-
tage of continuous reduction in size of the tumor target, allows
variation in dosimetry, and reduces radiation exposure to
treating personnel.16,17 It remains difﬁcult to compare the
superiority of either methods due to lack of randomized trials,
poor methodology in reporting complications, and loss of a
large number of patients to follow-up in most studies.18 In a
study of approximately 2000 patients, Lorvidhaya et al.19 re-
ported similar survival and complications at each disease stage
between patients undergoing high- and low-dose-rate brachy-
therapy. Conventional high-dose radiation therapy for bulky
Cervical cancer, HDR, Brachytherapy 17tumors certainly results in a high rate of complications, such as
rectovaginal ﬁstula, vesicovaginal ﬁstula, stricture ureter, and
vaginal necrosis and stenosis, due to the need higher doses
and/or tumor invasion.11
Pulsed Dose Rate (PDR) brachytherapy attempts to im-
prove upon the unfavourable radiobiology of the high dose
rate brachytherapy which delivers radiation in high fraction
sizes while maintaining the ability to ﬁnely optimize dose dis-
tribution and eliminate the personnel exposure to radiation
through remote afterloading. Treatment is delivered fre-
quently, often once per hour for each treatment course. Bio-
logically, since each fraction comes before the complete
repair of the sublethal cellular damage, the tissue experience
the radiation as almost continuous, mimicking LDR brachy-
therapy Although, this approach incorporates the biological
advantage of LDR brachytherapy and the optimization advan-
tage of the HDR brachytherapy, it also has many disadvan-
tages including frequent treatments requiring inpatient
admission for each applicator insertion, lack of applicator sta-
bilization, and possibility of mechanical failure. Although
PDR has prospered in Europe and Asia, in the USA it has
ﬂoundered due to regulations by the Nuclear Regulatory Com-
mission (NRC) that require that a physicist and/or radiation
oncologist be present for each fraction, which is almost impos-
sible to accomplish in a long schedule in a hospital setting.20
In spite of implementing HDR brachytherapy strategy for
the treatment of cervical cancer for more than four decades,
wide variations in treatment modalities including different
fractionations, applicators and planning modalities still exist
and subsequently the optimum treatment scheme still remains
controversial. This observational study aimed to report the
experience of HDR brachytherapy in the treatment of patients
with cervical cancer, evaluating treatment induced toxicities
and treatment outcomes.2. Methods
2.1. Patients
From June 2008 to June 2009, 40 patients with squamous cell
carcinoma of cervix were treated with deﬁnitively concomitant
chemo-radiotherapy.
Clinical stage distribution of patients according to the
International Federation of Gynecology and Obstetrics
(FIGO) criteria was as follows: IB2 (25%), IIA (12.5%)
and IIB (62.5%). ECOG Performance status ranged from 0
to 2. Nineteen of 40 patients (47.5%) had pretreatment exam-
ination under anesthesia. Mean age was 48.5 years (range
from 31 to 70 years). Sixty percent of the patients had grade
2 disease, 37.5% had grade 3 disease and only one patient
(2.5%) had grade 1 disease. Forty-ﬁve percent of the patients
were smokers. Two patients (5%) were diabetic, one patient
had Ischemic vascular disease and one patient had colla-
gen–vascular disease.
Staging was performed in all patients through clinical
examination and was complemented by abdomino-pelvic com-
puted tomography (CT) and MRI. PET scan was not routinely
used. The initial complaint of most patients was post-coital
bleeding or abnormal vaginal spotting.
At presentation median hemoglobin was 11.4 (range 6.6–
13.7) 10–13 gm/dl. The range was 6.6: 13.7 gm/dl group withmedian 11.4 gm/dl. The median white blood cell count was
7.3 K (range 2.2 –17.6 k). The median platelet count was
325 k (range 87 –670 K): The median SGOT was 20 U/dl
(range 14–34) the median SGPT was 23 U/dl (range 14–55).
The mean creatinine level is 0.8 mg/dl, ranging from 0.4 to
1.1 mg/dl. All patients had normal liver function tests, sodium
and potassium levels in blood and fasting blood sugar levels.
No patients had HIV infection or uncontrolled co-morbidities.
No patients had prior invasive malignancy, prior radiother-
apy to the region of the study cancer, initial surgical treatment,
excluding diagnostic biopsy of the primary site, diagnostic lap-
aroscopy or nodal sampling, severe, active co-morbidity, de-
ﬁned as follows: unstable angina and/or congestive heart
failure requiring hospitalization in past 6 months, left ventricu-
lar ejection fraction <50%, transmural myocardial infarction
within the last 6 months, acute bacterial or fungal infection
requiring intravenous antibiotics at the time of registration,
respiratory illness requiring hospitalization or precluding study
therapy at the time of registration, or any uncontrolled condi-
tion, which in the opinion of the investigator, would interfere in
the safe and timely completion of study procedures.
2.2. External beam radiation therapy (EBRT)
Pelvis was treated to a total dose of 45 Gy in 5 weeks with a
four-ﬁeld technique (AP-PA and lateral opposed ﬁelds), using
beam energies of 10 to <15 MV. Patients were treated once a
day, 5 days a week with a fraction size of 1.8–2 Gy. Involved
lateral parametrium and/or involved pelvic nodes were
boosted with ﬁelds tailored to encompass known areas of dis-
ease to achieve a total parametrial dose (including the intracav-
itary treatment) of 60 Gy+5%. A minimum source-axis
distance of 100 cm and a minimum source-to-skin distance of
80 cm were used.
2.3. Radiation therapy ﬁelds
2.3.1. Simulation
All treatment ﬁelds were simulated and portal veriﬁcations were
done on the treatment unit. Treatment was delivered in the
prone or supine position at the discretion of the treating physi-
cian. Techniques to limit irradiation of the small bowel were em-
ployed including treatment with a full bladder and selective use
of a bellyboard, and use of small bowel contrast during simula-
tion. The distal aspect of cervico-vaginal disease was marked
with radio-opaque seeds or a radio-opaque vaginal tampon.
Barium or another radio-opaque device was used to localize
the rectum. CT scan (including treatment planning CT) or
MRI was used in for treatment planning. The tumor target vol-
ume including gross nodal disease was indicated on the simula-
tion ﬁlms or digitally reconstructed radiographs if CT planning
is utilized. Blocking was used in all ﬁelds to shield small bowel
and femoral heads while maintaining a margin of at least 1 cm
from common iliac nodes. The following borders were used:
2.3.2. AP-PA portals
Superior: One centimeter above the inferior aspect of the sacro-
iliac joints, extended ﬁeld up to a line splitting T11-T12 were
considered in selected patients.
Inferior: Transverse line below the obturator foramen or
3 cm below the most distal vaginal disease, to include the intro-
itus if necessary.
Figure 1 The applicator system consisted of an intrauterine
tandem with three different angles and paired colpostat.
Figure 2 Tandom and ring application.
18 T. Refaat et al.Lateral: Two centimeter lateral to widest true pelvic diam-
eter unless the distal 1/3 of the vagina is involved; then the
inguinal lymph nodes should also be treated.
2.3.3. Lateral portals
Superior/inferior borders: Identical to AP-PA ﬁelds: Anterior
border: A line drawn anterior to the symphysis pubis and at
least 1 cm anterior to common iliac nodes at L4-L5.
Posterior border: A line through the posterior sacrum to in-
clude the cervical disease with a margin of 3–4 cm.
Parametrial boost: AP-PA ﬁelds with inferior and lateral
borders identical to pelvic ﬁelds. Superior border was 1 cm
above the inferior aspect of the sacro-iliac joints with central
blocking which measured at least 4.5 cm in width at mid plane
and tailored to the position of the intra-cavitary system. A Par-
ametrial boost was performed in 24 patients (60%) with gross
Parametrial invasion. Dose of Parametrial boost ranged from
3.6 to 10.8 Gy, with a median of 9 Gy.
Dose speciﬁcations: Dose was prescribed at the isocenter of
the beams; the maximum and minimum doses in the target vol-
ume should be within ±5% of the dose at the isocenter.
2.4. Brachytherapy
HDR brachytherapy preferably started as early as week two,
based on tumor geometry. Once HDR brachytherapy begun,
at least one insertion was performed per week, with no external
beam therapy or chemotherapy given on the day of the inser-
tion. If the majority of the external beam radiation was com-
pleted, then two insertions per week could be done separated
by at least 48 h in order to complete all treatment within eight
weeks. Chemotherapy could be given with one HDR fraction
delivered after the completion of all the external beam
irradiation.
In cases of unsuitable conditions for intracavitary inser-
tion mainly due to poor tumor geometry, HDR brachyther-
apy was performed after completion of EBRT. Conditions
that prevented the timely initiation of brachytherapy include
hysterometry not easily performed, the os not visible, the
lateral extent of the tumor not be covered by effective dose,
the colpostats available not be accommodated due to the tu-
mor volume, or possibility of perforation due to the cervical
canal destruction by tumor. Twenty-four Gray to point ‘‘A’’
in four weekly fractions of 6 Gy was planned for all
patients.
The dose to points A, B, rectum, bladder were deﬁned as
follows: point ‘‘A’’: The point 2 cm along the intrauterine tan-
dem from the cervical os or ﬂange of the tandem and then 2 cm
laterally in the plane of the intra-cavitary system. Point ‘‘B’’:
The point 5 cm lateral from a point 2 cm vertically superior
to the cervical os or ﬂange of the central tandem along the pa-
tients’ midline. Bladder Dose: the point in the center (in the
superior–inferior plane) of a contrast-ﬁlled balloon of a Foley
catheter and closest to the applicator system on a lateral view,
as deﬁned by ICRU 38. Rectal Dose: the dose at a point 0.5 cm
posterior to the vaginal ovoid or vaginal packing in the lateral
projection, deﬁned by ICRU 38.
HDR brachytherapy was applied using an Iridium-192
source (Ir-192) with nominal activity of 10 Ci. The applicator
system consisted of an intrauterine tandem with three different
angles and paired colpostats (Fig. 1). Types of colpostats were
selected based on the individual’s anatomy. Tandem and ring
applicators were used in some patients (Fig. 2).During each insertion, whenever possible, a rectal retractor
and an anterior vaginal packing were used to maximize the dis-
tance between the sources and the anterior rectal wall and pos-
terior bladder. When the placement of rectal retractor was not
possible, both the posterior and anterior vaginal walls were
packed with radio-opaque gauze to reduce rectal and bladder
doses and to visualize the posterior vaginal septum.
HDR brachytherapy dosimetric planning was performed
using PLATO system developed by Nucletron. Orthogonal
ﬁlms were taken to verify the placement of the applicators
and to perform the dosimetric plan. The prescribed dose was
computed to point ‘‘A’’. Based on linear quadratic model, bio-
logic effective dose (BED) to point ‘‘A’’, resulting from contri-
bution of EBRT and HDR brachytherapy, was determined for
all patients, using a tumor a/b value of 10. The rectal and blad-
der reference points were determined according to the Interna-
tional Commission of Radiation Units and Measurements
(ICRU), Report 38, guidelines for rectal and bladder doses.
Total BED at rectal and bladder reference points were
determined by adding the components of EBRT and HDR
brachytherapy, with an a/b value of 3, which is used for late-
responding tissues.
MRI image guided brachytherapy planning based on GEC
ESTRO Guidelines were used in four patients. The dose was
prescribed to High Risk CTV and Intermediate Risk CTV
based on the initial tumor burden shown in pre-treatment
MRI and the residual tumor burden shown in Post-External
Beam Radiation Therapy MRI. (Fig. 3).
Figure 3 Different view for plan evaluation.
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Dose volume histograms (DVH) were used for plan evaluation
with ultimate goal of delivering 85 Gy to High Risk CTV and
60 Gy to Intermediate Risk CTV while delivering less than
100% of the prescribed dose to less than 2 cc of Organs At
Risk (OAR) which were considered to be the rectum, bladder
and sigmoid. As per our predesigned clinical protocol; the dose
was recorded in all patients to point ‘‘A’’ right, point ‘‘A’’ left,
point ‘‘B’’ right, point ‘‘B’’ left, bladder and rectum.
2.5. Chemotherapy
All patients underwent cisplatin chemotherapy concurrent
with Radiation Therapy. The cisplatin was administered
weekly for 5 or 6 weeks with dose 40 mg/m2. Before chemo-
therapy administration, physical examinations, complete
blood counts, and liver and renal function tests were per-
formed. If the absolute neutrophil count was <1500/mm3 or
the platelet count was <75,000/mm3, chemotherapy was de-
layed or interrupted until the patient recovered. Patients were
prehydrated with two liters of D5/1/2 NS and 40 mEq KCL or
NS. Cisplatin was given over 30–60 min followed by 1L of D5/
1/2/NS. At least three liters of ﬂuids over the ensuing 24 h
either parenterally or orally was delivered.
Acute treatment-related toxicities, measured from the initi-
ation of chemo-radiotherapy to 3 months after completion,
were assessed using patient history, physical examination ﬁnd-
ings, and complete blood count results, using the National
Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.1.
2.6. Follow-up
Patient follow-up was performed every 3 months. Clinical
examination and cervical cytology were taken at eachTable 1 Dose delivered to ICRU 38 reference points.
Point ‘‘A’’ right total dose Point ‘‘A’’ left total do
Mean 85.15 85.58
STD 1.65 2.21
SEM 0.26 0.35
Median 85.13 85.13
Range 80.1: 90.0 80.1: 90.3follow-up. Chest radiograph and abdomino-pelvic CT were
done every 6 months. Local recurrence was deﬁned as disease
was detected centrally or in the parametrium within the true
pelvis.
Recurrences were deﬁned as distant if they occurred in the
para-aortic lymph nodes or elsewhere outside the pelvis. Fol-
low-up time was deﬁned by the interval between the ﬁrst day
of radiotherapy and the last information about the patient.
Patients considered lost to follow-up were those known to be
disease free when last seen and who did not return for their
scheduled follow up visits.3. Results
The total doses delivered to point ‘‘A’’ and B on the left and
right are listed in Table 1. As the dose and the number of frac-
tions of HDR brachytherapy were the same for all patients, the
variation of BED to point ‘‘A’’ was due to the different doses
of EBR and applicators positioning. Table 1 summarizes the
doses delivered to these reference points.
Total BED at rectal and bladder reference points were
determined by adding the components of EBRT and HDR
brachytherapy, considering an a/b value of 3, which is used
for late-responding tissues. The rectal point ranged from
5884.109 cGy to 7377.72 cGy, with a mean of 6198.22 cGy,
and the total dose at the bladder point ranged from
6288 cGy to 8297.7 cGy, with a mean of 7090.26 cGy.
Median follow-up time for all patients was of 20 months
(range 8–28 months, mean 19.5 months). At the time of this
analysis, 37 patients (92.5%) were alive with no evidence of
disease, one patient (2.5%) was alive with distant metastasis,
two patients (5%) was alive with local recurrence, and none
of the patients died due to either recurrent or inter-current dis-
ease nor complications. (Table 2).
Overall survival and disease-free survival at a mean of
20 months for all patients was 100% and 92.5%, respectively.
Local control was continued until the time of the analysis in 38
patients (95%). Two patients (5%) developed recurrent disease
and one patient out of forty patients (2.5%) developed distant
metastases. Bone was the site of distant metastases. Table 3
shows the patterns of failure.
3.1. Treatment induced complications
The most common reported side effect was fatigue that was
experienced by 30% of the patients. Grade 1 or 2 anemia
and neutropenia were present in 22.5% and 25% of the
patients. Grade 1/2 vomiting was reported in 22.5% of the
patients that was tolerated and most probably related to che-
motherapy administration. Diarrhea was of signiﬁcant impact
– Grade 3/4 – in 5% of the patients while Grade 1/2 diarrhea
was reported in 20% of patients.se Point ‘‘B’’ right total dose Point ‘‘B’’ left total dose
63.08 63.72
2.58 3.45
0.41 0.54
63.50 62.30
57.7:69.1 58.8:73.8
Table 2 Follow up.
Patient status at analysis Number of patients Percentage (%)
Alive without disease 37 92.5
Alive with distant
disease
1 2.5
Alive with local
recurrent disease
2 5
Died of recurrent/
intercurrent disease
0 0
Died of complication 0 0
Total 40 100
Table 3 Pattern of failure.
Patterns of failure Number of patients Percentage (%)
Local failure 2 5
Distant metastases 1 2.5
Both 0 0
Total 3 7.5
20 T. Refaat et al.Regarding rectal complications; two patients – 5% – devel-
oped grade 3/4 proctitis that led to grade 3/4 rectal bleeding
that required medical intervention while four patients – 10%
– had Grade 1/2 proctitis that led to grade 1/2 rectal bleeding.
Five patients – 12.5% – reported grade 1/2 urinary frequency
that was correlated to the effect of radiation on urinary blad-
der. The total BED to rectum and bladder reference points at
different levels was the predictive factor analyzed for incidence
of treatment induced complications in rectum and bladder,
respectively (see Table 4).
4. Discussion
This study aimed to determine the feasibility and tolerance of
Intracavitary High Dose Rate brachytherapy after External
Beam Radiotherapy to the pelvis with or without Para-aortic
region combined with weekly cisplatin. The target population
was female patients diagnosed with Stage IB2 and Stage II cer-
vical cancer that is conﬁrmed histopathologically and assigned
for concomitant chemoradiotherapy deﬁnitive treatment.
Concomitant radiotherapy and platinum-based chemother-
apy is the standard of care for patients with locally advanced
cervical. Based on randomized studies that showed a 12% ben-
eﬁt of the addition of chemotherapy to radiotherapy, this com-
bination has been implemented since 1999.21
Chemoradiotherapy reduced local and distant recurrence
and progression and improved disease-free survival. There
was a suggestion of a difference in the size of the survival ben-
eﬁt with tumor stage, but not across other patient subgroups.
Acute hematologic and GI toxicity was increased with chemo-
radiotherapy, but data were too sparse for an analysis of late
toxicity. There is no solid data regarding increased late toxicity
after chemoradiation compared with radiotherapy alone.22–24
This study included 40 patients in total who were treated
with High Dose Rate brachytherapy after External Beam
Radiotherapy concomitant with Cisplatin Chemotherapy.
All the patients had thorough laboratory evaluation prior
to treatment start that included Complete Blood Picture,Renal Function Tests, Liver Function Tests, Fasting Blood
Glucose and Electrolytes.
All the patients had pretreatment MRI for accurate evalu-
ation of tumor topography. Some of the patients had pre-
treatment PET scan in the suspicious cases.
Initial whole pelvis treatment to both groups ranged from
44 to 50 Gy. The parametrial boost to patients in both groups
was usually according to initial parametrial inﬁltration or
residual gross disease after whole pelvis external beam radia-
tion therapy. Whole pelvis External Beam Radiation Therapy
was the standard as per the predesigned protocol of this study.
Para Aortic Field was used only if histopathologically con-
ﬁrmed Para Aortic LN involvement in the PDR arm and for
PET positive Para Aortic LN in the HDR arm.
All the patients received weekly concomitant chemotherapy
cisplatin 40 mg/m2. Chemotherapy was well tolerated and was
not interrupted in any of the patients. All the patients in both
treatment groups had Partial Response after External Beam
Radiation Therapy concomitant with chemotherapy. The most
common system still in use for treating cervical cancer with
brachytherapy is the Manchester system. Using this system, it
was recognized that cervical cancers with larger primary tumors
and higher International Federation ofGynecology andObstet-
rics (FIGO) stage require higher doses of radiation to point ‘‘A’’
for locoregional control24 in comparison with lower stages.
Conformal brachytherapy has been made possible with ad-
vances in both imaging and treatment delivery technology. It is
now possible to locate and assess tumor bulk using magnetic
resonance imaging (MRI).25 This provides the ability to accu-
rately estimate the tumor volume with MRI.26,27
Radiotherapy and in particular brachytherapy (BT) have
been major treatment modalities for cervical cancer for
100 years. Despite major breakthroughs in other areas of
BT, there has been, until relatively recently, little technological
development in gynaecological BT. BT in cervical cancer is still
widely based on 2D X-ray imaging, limited individualization,
and prescription of dose according to point ‘‘A’’. We believe
that brachytherapy practice is very diverse across different
countries and institutions. However, in the late 1990s MR im-
age guided BT (IGBT) was initiated,28,29 and recommenda-
tions from the GEC-ESTRO working group introduced
MRI-based target concepts and 3D dose volume evaluation
and reporting.30,31 Implementing MRI image guided brachy-
therapy into practice have signiﬁcantly improved the possibil-
ities to optimize, to record and report doses in a reproducible
way as already demonstrated in a number of institutional
reports.28,32,33
A common language has been developed that allows differ-
ent BT traditions to communicate. Important steps and chal-
lenges in MRI-based IGBT have been investigated and
described in several publications with regard to: contour-
ing,34–36, dose optimization28,32,34,37,33,36 and applicator recon-
struction.38–43
Based on the clinical experience collected so far, the MRI-
based IGABT approach is expected to have a major impact on
the clinical outcome with a concomitant decrease in the rates
of both local failure and morbidity.44
With the introduction of an MRI-based target concept it is
possible to move from prescription at point ‘‘A’’ to prescrip-
tion of dose to a 3D target volume in terms of dose volume his-
togram (DVH) parameters. Furthermore, dose optimization
can be performed based on MR image guidance, whereby
Table 4 Treatment induced toxicities.
Toxicity Grade 1/2 Grade 3/4
Crude incidence Percentage (%) Crude incidence Percentage (%)
Anemia 9 22.5 – –
Neutropenia 10 25 – –
Diarrhea 8 20 2 5
Vomiting 9 22.5 – –
Fatigue 12 30 – –
Rectal bleeding 4 10 2 5
Proctitis 4 10 2 5
Urinary frequency 5 12.5 – –
Cervical cancer, HDR, Brachytherapy 21standard loading patterns are modiﬁed to come to an individ-
ually sculpted pear-shaped isodose which is tailored to target
and organs at risk at the time of BT.45
In the process of moving from 2D (X-ray and standard
loading) to 3D (MRI) target deﬁnition and dose optimization
it is essential to relate the classical dose prescription and stan-
dard loading patterns to the new routes of 3D dose prescrip-
tion and dose optimization. In our study we assessed the
relation between point doses and 3D DVH parameters that re-
sulted in statistically signiﬁcant differences in all the reference
point doses ‘‘Points A right, A left, B right and B left’’ and to
evaluate the improvement of DVH parameters when applying
MRI-based IGBT and its impact on treatment toxicity and
outcome that revealed better toxicity proﬁle when applying
the MRI image guided brachytherapy and similar treatment
response including Response Rate, Disease Free Survival and
Overall Survival.
In this study, tandem and ovoid applicators were used in
most of the HDR applicators. A tandem and ring applicator
was used in few cases according to the tumor geometry and
availability. The tandem and cylinder was never applied.
MRI image guided brachytherapy planning based on GEC
ESTRO Guidelines were used in few patients. The dose was
prescribed to High Risk CTV and Intermediate Risk CTV
based on the initial tumor burden shown in pre-treatment
MRI and the residual tumor burden shown in Post-External
Beam Radiation Therapy MRI.
PLATO planning system was used in planning all the cases.
Dose Volume Histograms – DVH – were used for plan evalu-
ation with ultimate goal of delivering 85 Gy to High Risk CTV
and 60 Gy to Intermediate Risk CTV while delivering less than
100% of the prescribed dose to less than 2 cc of Organs At
Risk ‘‘OAR’’ namely; Rectum, Bladder and Sigmoid. As per
our predesigned clinical protocol; the dose was recorded to
point ‘‘A’’ right, point ‘‘A’’ left, point ‘‘B’’ right, point ‘‘B’’
left, bladder and rectum.
Regarding the treatment induced hematological toxicities;
the treatment was well tolerated where 77.5% of all the pa-
tients did not experience any grade of anemia during the treat-
ment. Seventy-ﬁve percent of all the patients did not experience
any grade of neutropenia during the treatment. Regarding
platelets count, 98.75% of all the patients did not experience
any grade of thrombocytopenia during the treatment.
Twenty percent of the patients reported a grade 1/2 diar-
rhea compared to only 5% experienced grade 3/4 diarrhea.
Thirty percent of the patients had fatigue and 22.5% had vom-
iting. Four patients experienced grade 1/2 rectal hemorrhage
compared to only two patients who had grade 3/4.Our results are comparable to those reported in two ran-
domized trials conducted by the Gynecology Oncology
Group7,9 and in the study of the National Cancer Institute of
Canada Clinical Trials Group (NCIC CTG).46 In the study
by Rose et al.9 grade 3 and 4 leukopenia occurred in 21%
and 2% of patients, grade 3 and 4 GI toxicity in 8% and 4%
patients, and genitourinary grade 3 and 4 adverse effects oc-
curred in 3% and 2% of patients, respectively. In the trial by
Keys et al.7 using preoperative EBRT and brachytherapy com-
bined with weekly cisplatin, grade 3 and 4 hematologic toxici-
ties were observed in 18% and 3% of patients and GI
toxicities in 9% and 5% of patients, respectively, compared
with 2% moderate hematologic and 2% and 3% moderate
and severe GI toxicity, respectively, in the group assigned to
RT alone. These adverse effects were almost exclusively
transient.
In the trial by Pearcey et al.46 the signiﬁcant (grade 3 or
worse) acute side effects, most commonly GI, hematologic,
and genitourinary toxicity, were observed more frequently
but still occasionally in the combined modality arm and this
was not associated with clinically important treatment delays.
In our study, we report better toxicity proﬁle that is most prob-
ably correlated to the advanced conformal brachytherapy uti-
lized in this study and the improvement in planning and
sparing of Organs at Risk. There might be an element of po-
tential underreporting of some toxicities owing to some ﬁles
based data collection.
Good tolerance of concurrent cisplatin and RT has also
been reported in smaller series.47–49 Malfetano et al.47 com-
bined weekly cisplatin at a dose of 1 mg/kg (up to 60 mg) with
extended-ﬁeld RT (including para-aortic lymph nodes) and
brachytherapy. Administration of cisplatin (mean ﬁve cycles,
range one–six) was accompanied by minimal morbidity (no
grade 4 neutropenia or thrombocytopenia) and no nephrotox-
icity, ototoxicity, or neurotoxicity. Of 67 patients, 10 had their
chemotherapy withheld secondary to leukopenia. RT was not
interrupted in any patient. Boronow48 observed no Grade 4
hematologic toxicity during postoperative chemoradiotherapy
with cisplatin (20 mg/L/24 h for a 96-h infusion during weeks
1, 4, and 7) and extended-ﬁeld RT. All patients completed their
treatment schedule without breaks. Omura et al.50 observed
only occasional Grade 3 or 4 hematologic, GI, and renal tox-
icity (0.7%, 0.7%, and 1.5%, respectively) in the group of pa-
tients treated with RT and cisplatin (50 mg/m2 every 3 weeks,
up to six cycles). In their study, Grade 1–3 neurotoxicity (both
peripheral and central, all reversible) occurred in 5% of pa-
tients. In another study, RT with concurrent cisplatin
(50 mg/m2 every 10 days) was accompanied by Grade 4 acute
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patients.53
A review of treatment induced acute toxicity included 4590
cervical cancer patients enrolled in 19 randomized trials, of
which 12 used platinum based chemotherapy revealed on aver-
age GI and genitourinary toxicity incidence of grade 3 and 4
(8.0% and 1.5%, respectively) that is considerably higher to
the respective ﬁgures in our study, same for grade 3–4 leukope-
nia (16.4%) and thrombocytopenia (1.7%) that occurred more
frequently.52
Hypomagnesemia caused by enhanced renal excretion of
magnesium is reported as cisplatin induced toxicity. These se-
quelae may lead to secondary hypocalcemia with subsequent
tetany symptoms. Hypomagnesemia is reported in up to
90% of patients if no corrective measures are undertaken.
However, the clinical relevance of this ﬁnding remains uncer-
tain.53 grade 3 and 4 hypomagnesemia, possibly accompanying
cisplatin administration, was reported in 3 of 176 patients trea-
ted in the GOG trial.9 In this trial, hypomagnesemia occurred
in 48% of patients assigned to RT and weekly cisplatin. How-
ever, in our study pretreatment serum electrolyte assay did not
included magnesium measurements, myoclonia after cisplatin
infusions was never reported.
The short follow-up for most of the patients analyzed in
this study – median of 20 months – did not allow for a reliable
assessment of late toxicity. No apparent difference in late ad-
verse effects between RT alone and RT plus weekly cisplatin
was reported in either the GOG trial7 or the NCIC CTG
trial.46
In the former, the most common Grade 3 and 4 side effects
were those from large bowel or rectum, small bowel, and blad-
der. In the study by Pearcey et al.51 the most common was gen-
itourinary toxicity, but, again, no statistically signiﬁcant
difference was found in the incidence of late effects between
the two arms. No increased risk of late complications associ-
ated with the addition of cisplatin and 5-ﬂuorouracil to RT
was also reported in a Radiation Therapy Oncology Group
study, although acute toxicity was much greater in the patients
who underwent chemoradiotherapy.8
The median follow up that was 20 months in the HDR arm
shows three patients failed during the follow up; two local fail-
ures and one distant metastasis were. There was no statistical
signiﬁcant probability of correlation between total dose deliv-
ered to point ‘‘A’’ and treatment failure.
In an analysis that included 141 patients with cervix cancer
(stages IB–IVA) treated with 45–50.4 Gy EBRT ± cisplatin
plus 4_7 Gy IGBT. Gross tumour volume (GTV), high risk
clinical target volume (HR CTV) and intermediate risk CTV
(IR CTV) were delineated and DVH parameters (D90,
D100) were assessed. Groups of patients were formed accord-
ing to tumour size at diagnosis (GTVD) of 2–5 cm (group 1) or
>5 cm (2), with subgroups of the latter for HR CTV size at
ﬁrst IGBT 2–5 cm (2a) or > 5 cm (2b). Eighteen local recur-
rences in the true pelvis were observed. Dose–response analy-
ses revealed a signiﬁcant effect of HR CTV D100 (p= 0.02)
and D90 (p= 0.005). The authors concluded that signiﬁcant
dependence of local control on D100 and D90 for HR CTV
was found. Tumour control rates of >90% can be expected
at doses >67 Gy and 86 Gy, respectively.54 This data is rele-
vant to our ﬁndings where we had 92.5% local control of tu-
mor over a median follow up of 18 months.So far, no solid data on statistically signiﬁcant large pop-
ulation and long term follow up is available for the MRI im-
age guided brachytherapy in cervical cancer. Further data on
dose volume relationships in cervical cancer radiotherapy are
expected from an ongoing prospective multicentre study on
MRI-guided BT in cervical cancer: EMBRACE (www.
clinicaltrials.org, www.embracestudy.dk). This study will
hopefully for the ﬁrst time make it possible to reach a critical
mass of patients which will be large enough to obtain credible
data on key volumetric, dosimetric, clinical and biological
parameters.
Another important factor that might be contributing to
treatment outcome is the tumor molecular proﬁling and its im-
pact on treatment response, disease free survival and overall
survival. Being able to predict which patients are likely to have
a recurrence after standard therapy through tumor molecular
proﬁling and biomarker studies is likely to improve overall
outcome in these patients by helping to select those who may
beneﬁt from individualized targeted therapies.
Nuclear factor kappa B (NF-jB) is a transcription factor
whose role in the pathogenesis of a wide variety of tumor types
including cervical cancer has been well described.55–57 Cumula-
tive evidence suggests that this protein functions as a mediator
of cellular survival, inﬂammation, angiogenesis, and treatment
resistance through regulation of the transcription of over 200
target genes. Nuclear factor kappa B has recently become a
major target for cancer drug development, as shown by the
many nonspeciﬁc natural and synthetic compounds shown to
exert their therapeutic effects at least in part through the inhi-
bition of NF-jB.58,59 Furthermore, recent preclinical and clin-
ical studies that combine these agents with radiation and
chemotherapy have shown promising results.58–60
The role of NF-jB as a potential prognostic biomarker has
only recently been explored. In several cancers including
breast, prostate, skin, lung, and pancreas, NF-jB nuclear
expression has correlated with poor clinical outcome.61–65
Recently, eighteen patients with locally advanced cervical
cancer were enrolled in a study in which cervical biopsy spec-
imens were obtained before radiation therapy and 48 h after
treatment initiation. Matched biopsy specimens from 16 of
these patients were available and evaluated for the nuclear
expression of NF-jB protein by immunohistochemical stain-
ing. After a median follow-up of 43 months, there were nine
total treatment failures. Nuclear staining for NF-jB was posi-
tive in 3 of 16 pretreatment biopsy specimens (19%) and 5 of
16 postradiation biopsy specimens (31%). Pretreatment
expression of NF-jB nuclear staining correlated with increased
rates of local–regional failure (100% versus 23%, p= 0.01),
distant failure (100% versus 38%, p= 0.055), disease-speciﬁc
mortality (100% versus 31%, p= 0.03), and overall mortality
(100% versus 38%, p= 0.055).66
The authors suggested that pretreatment nuclear expression
of NF-jB may be associated with a poor outcome for cervical
cancer patients treated with chemoradiation. Although these
data require validation in a larger group of patients, the results
support the continued study of the relationship between NF-
jB and outcome in patients treated for carcinoma of the cer-
vix.66 Unfortunately, our study did not put into consideration
the molecular proﬁling of the enrolled patients; however we
will be strongly endorsing future research and clinical trials
in this direction.
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